ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings Inc (CERO)

2,96
-0,74
(-20,00%)
Fermé 11 Janvier 10:00PM
2,971
0,011
(0,37%)
Après les heures de négociation: 1:58AM

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
2,971
Prix Achat
2,95
Prix Vente
3,13
Volume échangé
591 353
2,831 Fourchette du Jour 3,32
2,90 Plage de 52 semaines 1 238,00
Clôture Veille
3,70
Ouverture
3,32
Dernière Transaction
12
@
3.11
Dernière heure de transaction
Volume moyen (3 m)
99 811 761
Volume financier
US$ 1 774 672
VWAP
3,001

CERO Dernières nouvelles

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

SOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance...

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) --   CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next...

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next...

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an...

CERo Therapeutics, Inc. Provides Corporate Update

Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation...

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Company requests Type A Meeting with U.S. Food and Drug Administration regarding clinical hold for CER-1236; announces key management changes SOUTH SAN FRANCISCO, Calif., Sept. 25, 2024 (GLOBE...

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

Company anticipates initial human trials to focus on AML upon IND clearance SOUTH SAN FRANCISCO, Calif., July 08, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq:...

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) --  CERo...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-2.999-50.23450586265.9710.252.92648272755.15737426CS
4-3.8291-56.30946603736.800110.252.91068866535.4823502CS
12-5.789-66.08447488588.7644.772.99981176117.62250251CS
26-14.929-83.402234636917.944.772.94933343217.18244359CS
52-522.029-99.434095238152512382.92853638920.47536936CS
156-522.029-99.434095238152512382.92853638920.47536936CS
260-522.029-99.434095238152512382.92853638920.47536936CS

CERO - Frequently Asked Questions (FAQ)

What is the current CERo Therapeutics share price?
The current share price of CERo Therapeutics is US$ 2,971
What is the 1 year trading range for CERo Therapeutics share price?
CERo Therapeutics has traded in the range of US$ 2,90 to US$ 1 238,00 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
VRMEVerifyMe Inc
US$ 2,57
(52,98%)
57,83M
WKEYWISeKey International Holdings AG
US$ 10,041
(52,83%)
6,72M
DATSDatChat Inc
US$ 4,8105
(49,86%)
158,65M
CDTConduit Pharmaceuticals Inc
US$ 0,1214
(48,05%)
1,17B
INTZIntrusion Inc
US$ 2,8888
(44,44%)
40,61M
IGMSIGM Biosciences Inc
US$ 2,095
(-66,21%)
5,69M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1,87
(-51,30%)
2,28M
MODVModivCare Inc
US$ 6,51
(-47,88%)
2,73M
AIFUAIX Inc
US$ 0,420501
(-47,76%)
7,83M
MRSNMersana Therapeutics Inc
US$ 0,691
(-46,85%)
58,31M
CDTConduit Pharmaceuticals Inc
US$ 0,1214
(48,05%)
1,17B
NVDANVIDIA Corporation
US$ 135,91
(-3,00%)
207,53M
RGTIRigetti Computing Inc
US$ 8,9299
(-11,06%)
178,82M
VMARVision Marine Technologies Inc
US$ 2,14
(40,79%)
175,57M
DATSDatChat Inc
US$ 4,8105
(49,86%)
158,65M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock